Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market

Reportstack's latest report forecasts that Major Depressive Disorder market to witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%.
 
SAN FRANCISCO - Oct. 2, 2014 - PRLog -- The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up  until the end of 2023, thanks to the potential launch of new treatments following the patent  expirations of top-selling products, says a new report from Reportstack.

According to the company’s latest report "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023" , the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%.
However, forecasts say that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly’s Cymbalta, Otsuka Pharmaceutical/BMS’ Abilify and AstraZeneca’s Seroquel XR.

Toli Koutsokeras, Ph.D., GlobalData's Senior Analyst covering Neurology, says: “Additionally, there are a number of significant needs in the depression therapeutics market that are yet to be addressed. These include the requirement for products that demonstrate improved efficacy, more favorable safety profiles and a rapid onset of antidepressant effects. Ample opportunity therefore exists for players looking to develop and potentially introduce therapies, which can
address these unmet needs, into this arena.”

There are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck’s brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma’s cariprazine, Alkermes’s ALKS-5461 and Naurex’s GLYX-13, along with antidepressant therapies, including Euthymics Bioscience’s amitifadine, Lundbeck/Takeda’s
tedatioxetine and e-Therapeutics’ ETS6103

Koutsokeras continues: “All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects.
“With their ability to address some of the MDD treatment market’s key unmet needs, we believe that these products’ launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda’s Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023.”

This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market.

Complete report available @ http://www.reportstack.com/product/174615/pharmapoint-maj...

Other MDD Market Reports from Reportstack:
Major Depressive Disorder - Pipeline Review, H2 2014 (http://www.reportstack.com/product/166294/major-depressiv...)

Contact
Debora White
debora@reportstack.com
08887896604
End
Source: » Follow
Email:***@reportstack.com
Posted By:***@reportstack.com Email Verified
Tags:Major Depressive Disorder, Pharma Market, Market Research, Neurology, Medical Research
Industry:Health, Medical
Location:San Francisco - California - United States
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Reportstack PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share